Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced that on February 2, 2026 the Compensation Committee granted restricted stock unit awards covering an aggregate of 2,964 shares to eight new non-executive employees under the 2024 Inducement Plan.

The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date.

Key Figures

Inducement RSUs: 2,964 shares New employees: 8 employees Vesting schedule: 4 annual installments +5 more

8 metrics

Inducement RSUs 2,964 shares Aggregate restricted stock unit awards to new employees

New employees 8 employees Non-executive hires receiving inducement RSUs

Vesting schedule 4 annual installments RSUs vest in four equal annual installments

Plan year 2024 Inducement Plan Equity plan used for inducement grants

Current price $310.52 Pre-news share price for PRAX

Price vs 52-week high -5.01% Distance from 52-week high of $326.91

52-week low $26.70 52-week low level for PRAX

Market cap $8,574,368,906 Pre-news market capitalization

Market Reality Check

Price: $303.34 Vol: Volume 509,009 vs 20-day ...

normal vol

$303.34 Last Close

Volume Volume 509,009 vs 20-day average 612,380; volume_relative at 0.83 indicates below-average trading. normal

Technical Shares at $310.52, trading above 200-day MA at $118.03, reflecting a strong pre-news uptrend.

Peers on Argus

PRAX was up 0.46% while peers showed mixed moves: AVXL (-2.44%), EYPT (-3.69%), ...

PRAX was up 0.46% while peers showed mixed moves: AVXL (-2.44%), EYPT (-3.69%), NKTR (+2.09%), SANA (-3.92%), ZBIO (+7.52%). This points to stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Leadership appointment	Positive	+1.9%	Appointment of epilepsy expert Dr. Orrin Devinsky to lead clinical strategy.
Jan 12	Strategic update	Positive	-4.4%	Outlined 2026 priorities, late-stage successes, NDAs and strong balance sheet.
Jan 09	Inducement grants	Neutral	-4.4%	RSU inducement awards of 434 shares to three new employees under 2024 plan.
Jan 08	Board/executive changes	Positive	-2.0%	New board members and executive promotions to support late-stage growth.
Jan 06	Public offering	Negative	-1.4%	Pricing of $575M offering at $260 per share with overallotment option.

Pattern Detected

Recent news shows mixed price reactions: governance and strategic updates often saw negative moves, while leadership hires and financing news had both positive and negative follow-through.

Recent Company History

Over the past month, PRAX reported several key developments, including a major public offering on Jan 6, 2026, board and executive changes on Jan 8, 2026, and strategic leadership and pipeline updates on Jan 12–13, 2026. It also disclosed prior inducement grants under the 2024 Inducement Plan. Price reactions ranged from about -4.41% on growth and financing updates to +1.85% on a senior clinical hire, highlighting uneven market responses to otherwise constructive corporate news.

Market Pulse Summary

This announcement details a modest inducement grant of 2,964 restricted stock units to eight new non...

Analysis

This announcement details a modest inducement grant of 2,964 restricted stock units to eight new non-executive employees under the 2024 Inducement Plan, vesting over four annual installments. Such grants are routine tools for attracting talent under Nasdaq Listing Rule 5635(c)(4). In context, PRAX recently completed a sizeable public offering and multiple leadership changes, so investors may track ongoing equity-based compensation alongside capital structure developments and upcoming clinical and regulatory milestones.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), equity awards

3 terms

restricted stock unit financial

"granted restricted stock unit awards covering an aggregate of 2,964 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity awards financial

"used exclusively for the grant of equity awards to individuals who were not"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

AI-generated analysis. Not financial advice.

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on February 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,964 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What did Praxis (PRAX) announce about inducement grants on February 2, 2026?

Praxis granted restricted stock units totaling 2,964 shares to eight new non-executive employees as inducements. According to the company, the awards were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

How do the restricted stock units for PRAX vest and when are they earned?

The restricted stock units vest in four equal annual installments subject to continued employment. According to the company, each installment vests on successive annual anniversaries provided the employee remains employed through each vesting date.

Who is eligible for awards under Praxis's 2024 Inducement Plan (PRAX)?

The 2024 Inducement Plan covers individuals who were not previously employees or who had a bona fide non-employment period. According to the company, grants are used exclusively as material inducements to begin employment with Praxis.

Do the PRAX inducement awards affect executive officers or relate to major transactions?

No, the awards were granted to eight new non-executive employees and not to executive officers. According to the company, the grants were routine inducement awards and do not indicate a separate material transaction disclosed in this announcement.